Trending Now
Bullish run on equities grips the market
Today’s market action continues the bullish run in equities. All the major indices are higher. There are three stock sectors down on...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Sleep Technology Stocks Could Present an Outsized Opportunity (PRPL, APYP, TPX)
The global sleep apnea devices market size was valued at USD 3.7 billion in 2020 and is expected to expand at a...
MAKE IT MODERN
LATEST REVIEWS
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Appoints a New Chief Financial Officer
Adaptive Biotechnologies Corp (NASDAQ: ADPT) has appointed a new chief financial officer (CFO). Tycho Peterson, who will fill the role, has decades of experience...
MAKE IT MODERN
PERFORMANCE TRAINING
MorphoSys AG (NASDAQ:MOR) and Incyte Corporation (NASDAQ:INCY) Announce EU MAA validation Of Tafasitamab
MorphoSys AG (NASDAQ:MOR) and Incyte Corporation (NASDAQ:INCY) have announced the European Marketing Authorization Application (MAA) validation for the anti-CD19 antibody tafasitamab.
MorphoSys and Incyte seeking...
Invesco QQQ Trust Series 1 (NASDAQ:QQQ) suggest a bounce in the making
The QQQ’s failed at the $318 area resistance again this morning. Despite the CPI figure coming in at 5% for the year...
Halozyme Therapeutics Inc. (NASDAQ:HALO) Reports Strong Q3 With Revenue Of $65.3 Million
Halozyme Therapeutics Inc. (NASDAQ:HALO) has announced Q3 financial results in which revenue was $65.3 million and EPS of $0.25 and also provided an updated...
Vaccinex Inc. (NASDAQ:VCNX) On Track To Finalize Pivotal SIGNAL Study Of Pepinemab In Huntington’s...
Vaccinex Inc. (NASDAQ:VCNX) has announced that it is on track to finalize the potentially vital SIGNAL study in Huntington’s Disease (HD) on time despite...
CRISPR Therapeutics (NASDAQ:CRSP) Widens Net Loss To $79.7 Million In Q2 2020
CRISPR Therapeutics (NASDAQ:CRSP) widened its net loss to $79.7 million in Q2 2020 from $53.7 million in Q2 2020. Its collaboration revenue declined to less...
MAKE IT MODERN
